Non-comparative phase 2 trial in 120 patients ≥70 years with metastatic colorectal cancer: 6-month PFS rate was 68% with dose-reduced mFOLFOX7 and 46% with aflibercept plus mLV5FU2; grade ≥3 related SAEs 5% vs 17%.
RCTn = 120
Hofheinz et al. Aflibercept and 5-FU vs. FOLFOX as 1st line treatment for older adults or frail elderly patients with metastatic colorectal cancer - The randomized phase 2 AIO / IKF ELDERLY trial (AIO-KRK-0117 / IKF 629)